•
•
•
•
•
•
•
What the updated trivalent vaccines contain, who is recommended to get one, and where official guidance stands this autumn
Seasonal influenza vaccines are reformulated every year to match the viruses expected to circulate. For the 2026–27 Northern Hemisphere season, all three vaccine components were updated, and every influenza vaccine marketed in the United States is trivalent (two influenza A strains and one influenza B strain).
This guide summarizes what is new, who is recommended to be vaccinated, and why you may see slightly different advice depending on the source. It is general information, not medical advice. Talk to a doctor or pharmacist about your own situation.
| Area | 2026–27 update |
|---|---|
| Vaccine composition | All three virus components updated versus the previous season |
| Format | Trivalent vaccines only in the U.S. (two A strains, one B strain) |
| H3N2 | Update targets the A(H3N2) subclade K virus that spread widely in 2025–26 |
| Composition decision | The U.S. FDA announced its composition recommendations on March 13, 2026; the WHO published its Northern Hemisphere recommendation in February 2026 |
| Product availability | FluMist (nasal spray) is available for self- or caregiver administration; an mRNA vaccine (mFlusiva) was approved for adults over 50; Afluria is not available this season (per AAFP) |
Major medical bodies continue to recommend annual influenza vaccination for everyone aged 6 months and older who has no medical contraindication. Key points:
In the United States, the CDC issued interim guidance stating that the seasonal influenza recommendations in the July 2025 immunization schedule remain in effect for 2026–27. Separately, groups including the AAP, AAFP and other societies published their own respiratory-season recommendations covering influenza, COVID-19 and RSV, which several outlets described as filling a gap in federal guidance.
Outside the U.S., national programs set their own eligibility. England's NHS programme, Hong Kong's vaccine advisory committee and Belgium's Superior Health Council, for example, each publish season-specific recommendations. Check your own country's health ministry for local priority groups and timing.
Influenza viruses mutate continuously, so strain selection is reviewed annually and vaccines are updated to match circulating viruses.
No. Inactivated and recombinant vaccines cannot cause influenza. Mild, short-lived side effects such as a sore arm are common.
No. The composition is based on WHO recommendations, but eligibility, products and timing differ by country and between hemispheres.
CDC 2026–2027 flu season page; FDA/WHO composition announcements; AAFP and AAP 2026–27 guidance; Immunize.org; Healio.
